Skip to main content

Change in PDL Status for Antihyperuricemics Drug Class Effective April 22, 2024

Last updated on

On April 22, 2024, the Texas Health and Human Services Commission (HHSC) removed the non-preferred status from products with the brand name Mitigare on the HHSC preferred drug list (PDL).

The non-preferred status of the following drugs was removed:

National Drug Code (NDC)Drug Name
59467031801Mitigare 0.6 mg capsule
59467031810Mitigare 0.6 mg capsule
59467031830Mitigare 0.6 mg capsule

These changes will allow providers to prescribe the Mitigare products without requiring PDL prior authorization.

Note: The preferred status of products with the brand name Colcrys will not change, so that existing stock of these medications can be used and clients can continue accessing necessary medication.

Email vdp-formulary@hhsc.state.tx.us with any questions.